Tags

Type your tag names separated by a space and hit enter

Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Mol Neurobiol. 2020 Dec; 57(12):4921-4928.MN

Abstract

The global pandemic of novel coronavirus disease 2019 (COVID-19) has taken the entire human race by surprise and led to an unprecedented number of mortalities worldwide so far. Current clinical studies have interpreted that angiotensin-converting enzyme 2 (ACE2) is the host receptor for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). In addition, ACE2 is the major component of the renin-angiotensin system. ACE2 deteriorates angiotensin II, a peptide that is responsible for the promotion of stroke. The downregulation of ACE2 further activates an immunological cascade. Thus, researchers need to explore and examine the possible links between COVID-19 and ischemic stroke (IS). Human ACE2 expression level and pattern in various tissues might be decisive for the vulnerability, symptoms, and treatment outcomes of the SARS-CoV-2 infection. The swift increase in the knowledge of SARS-CoV-2 has given creditable evidence that SARS-CoV-2 infected patients also encounter neurological deficits. As the SARS-CoV-2 binds to ACE2, it will hamper the activity of ACE2 in providing neuroprotection, especially in the case of stroke patients. Due to the downregulation of ACE2, the inflammatory response is activated in the ischemic penumbra. The COVID-19 pandemic has affected people with various pre-existing diseases, including IS, in such a way that these patients need special care and attention for their survival. Several clinical trials are currently ongoing worldwide as well as many other projects are in different stages of conceptualization and planning to facilitate the effective management of stroke patients with COVID-19 infection.

Authors+Show Affiliations

Department of Toxicology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, 110062, India.Department of Toxicology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, 110062, India.Department of Communication Sciences and Disorders, Oklahoma State University, Stillwater, OK, 74078, USA.Division of Basic Medical Sciences, Indian Council of Medical Research, Ministry of Health and Family Welfare, Govt. of India, V. Ramalingaswami Bhawan, P.O. Box No. 4911, New Delhi, 110029, India.Department of Toxicology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, 110062, India. sparvez@jamiahamdard.ac.in.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32813238

Citation

Kaushik, Pooja, et al. "Cross-Talk Between Key Players in Patients With COVID-19 and Ischemic Stroke: A Review On Neurobiological Insight of the Pandemic." Molecular Neurobiology, vol. 57, no. 12, 2020, pp. 4921-4928.
Kaushik P, Kaushik M, Parveen S, et al. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic. Mol Neurobiol. 2020;57(12):4921-4928.
Kaushik, P., Kaushik, M., Parveen, S., Tabassum, H., & Parvez, S. (2020). Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic. Molecular Neurobiology, 57(12), 4921-4928. https://doi.org/10.1007/s12035-020-02072-4
Kaushik P, et al. Cross-Talk Between Key Players in Patients With COVID-19 and Ischemic Stroke: A Review On Neurobiological Insight of the Pandemic. Mol Neurobiol. 2020;57(12):4921-4928. PubMed PMID: 32813238.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic. AU - Kaushik,Pooja, AU - Kaushik,Medha, AU - Parveen,Sabiha, AU - Tabassum,Heena, AU - Parvez,Suhel, Y1 - 2020/08/19/ PY - 2020/05/12/received PY - 2020/08/11/accepted PY - 2020/8/20/pubmed PY - 2020/8/20/medline PY - 2020/8/20/entrez KW - Angiotensin-converting enzyme 2 KW - COVID-19 KW - Inflammatory response KW - Ischemic stroke KW - Renin-angiotensin system SP - 4921 EP - 4928 JF - Molecular neurobiology JO - Mol Neurobiol VL - 57 IS - 12 N2 - The global pandemic of novel coronavirus disease 2019 (COVID-19) has taken the entire human race by surprise and led to an unprecedented number of mortalities worldwide so far. Current clinical studies have interpreted that angiotensin-converting enzyme 2 (ACE2) is the host receptor for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). In addition, ACE2 is the major component of the renin-angiotensin system. ACE2 deteriorates angiotensin II, a peptide that is responsible for the promotion of stroke. The downregulation of ACE2 further activates an immunological cascade. Thus, researchers need to explore and examine the possible links between COVID-19 and ischemic stroke (IS). Human ACE2 expression level and pattern in various tissues might be decisive for the vulnerability, symptoms, and treatment outcomes of the SARS-CoV-2 infection. The swift increase in the knowledge of SARS-CoV-2 has given creditable evidence that SARS-CoV-2 infected patients also encounter neurological deficits. As the SARS-CoV-2 binds to ACE2, it will hamper the activity of ACE2 in providing neuroprotection, especially in the case of stroke patients. Due to the downregulation of ACE2, the inflammatory response is activated in the ischemic penumbra. The COVID-19 pandemic has affected people with various pre-existing diseases, including IS, in such a way that these patients need special care and attention for their survival. Several clinical trials are currently ongoing worldwide as well as many other projects are in different stages of conceptualization and planning to facilitate the effective management of stroke patients with COVID-19 infection. SN - 1559-1182 UR - https://www.unboundmedicine.com/medline/citation/32813238/Cross_Talk_Between_Key_Players_in_Patients_with_COVID_19_and_Ischemic_Stroke:_A Review_on_Neurobiological_Insight_of_the_Pandemic_ L2 - https://dx.doi.org/10.1007/s12035-020-02072-4 DB - PRIME DP - Unbound Medicine ER -